Eric Singhi/faculty.mdanderson.org
Jul 22, 2025, 22:47
Eric Singhi: Combos May be in, but Informed and Shared Decision-Making Stays Key
Eric Singhi, Thoracic Medical Oncologist at MD Anderson Cancer Center, shared a post by Rami Manochakian, adding:
“Press release: FLAURA2 shows osimertinib + chemo improves OS in EGFR+ lung cancer — “statistically significant and clinically meaningful.” Combos may be in, but informed and shared decision-making stays key. Excited to review full data.”
Quoting Rami Manochakian‘s post:
“Hot Off the Press BigNews
Press Release by AstraZeneca
FLAURA2 trial of Osimertinib + Chemotherapy vs Osimertinib in 1st line Tx for patients with EGFR+ advanced Lung Cancer (NSCLC) shows:
Statistically Significant and Clinically Meaningful Improvement in Overall Survival.”
More posts featuring Eric Singhi.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 22, 2025, 22:17
Jul 22, 2025, 20:07
Jul 22, 2025, 19:29
Jul 22, 2025, 19:28